logo
Plus   Neg
Share
Email
Comment

Corcept Therapeutics Q4 Loss Widens

Corcept Therapeutics Inc. (CORT) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.

Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.

During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Citigroup Inc. on Tuesday reported a loss for the fourth quarter, reflecting the impact of a non-cash charge of $22 billion due to the recent U.S. tax reform that more than offset an increase in revenues. However, adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in line with expectations. Shares of BP Plc were losing around 2 percent in the morning trading in London after the British energy giant said Tuesday that it now expects to take a post-tax non-operating charge of around $1.7 billion in its fourth quarter for Deepwater Horizon settlement program. BlackBerry Ltd. has introduced a new a cloud-based cybersecurity program that will scan automakers' software for threats amid increased concerns about hacking in Internet-connected cars. BlackBerry Jarvis, the transformational software cybersecurity product, helps carmakers detect security flaws in software before it goes into their vehicles.
comments powered by Disqus
Follow RTT